Exhibit 99.1
![Graphic](https://capedge.com/proxy/8-K/0001558370-23-016030/azta-20230922xex99d1001.jpg)
Azenta Announces CFO Transition
Industry Veteran Herman Cueto Named CFO
Azenta CFO Lindon Robertson to Retire
Company Reaffirms Guidance for Fourth Quarter Fiscal 2023
BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ – Azenta, Inc. (Nasdaq: AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, who comes from BD (Becton, Dickinson and Company, NYSE: BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition.
Steve Schwartz, Azenta President and Chief Executive Officer, said, “We are thrilled to welcome Herman to Azenta. He brings a combination of extensive industry experience and finance expertise, including developing and executing strategies to reduce complexity and enhance value. I look forward to collaborating with him as we work to accelerate revenue growth, drive sustainable margin expansion and create value for shareholders as a pure-play life sciences company.”
Mr. Cueto joins Azenta from BD, which he joined in 2017 through its acquisition of C.R. Bard. Mr. Cueto most recently served at BD as Senior Vice President of Finance, overseeing Segments / Regions / BP&A / Operations. He formerly served as Senior Vice President and Chief Financial Officer of BD’s Medical Segment, BD’s largest operating unit, as well as overseeing finance’s functional responsibility for Operations and Global Supply Chain. Prior to BD, Mr. Cueto was at C.R. Bard for fourteen years, most recently as Vice President and Group CFO. He earned a Bachelor of Science and Master’s degree from Fairleigh Dickinson University and a Master of Business Administration degree from Seton Hall University. Mr. Cueto is also a Certified Public Accountant licensed in the State of New Jersey.
Mr. Cueto said, “I am excited to join Azenta at such a pivotal time for the Company and its industry. Azenta is known for its cutting-edge, life sciences technology and unique role in the sample management ecosystem. I look forward to working closely with Steve and team as Azenta continues to enable breakthroughs faster and bring essential therapies to those who need them most.”
Dr. Schwartz continued, “On behalf of the Board, management team and entire Company, we thank Lindon for his tremendous contributions to Azenta over the past decade. He has been instrumental in our financial and strategic positioning as we transformed from a small business within Brooks Automation, to a pure-play, publicly traded life sciences company generating more than $600 million in revenue. We are grateful to Lindon for his leadership and wish him all the best in his retirement.”